CANbridge Appoints Mark A. Goldberg as Acting Chief Medical Officer Raises Additonal Capital in Series a Plus Round


Beijing, China, October 20,, 2015 — CANbridge Life Sciences, a biopharmaceutical company focused on developing Western drug candidates in China and North Asia, has appointed Mark A. Goldberg, MD, as Acting Chief Medical Officer (CMO), to take effect immediately.

Dr. Goldberg brings to CANbridge over 30 years of clinical and industry experience as a seasoned oncologist, hematologist and corporate medical/regulatory strategist.  Prior to CANbridge, he was Executive Vice President, Medical and Regulatory Strategy at Synageva BioPharma Corporation. Dr. Goldberg joined Synageva in 2011 from Genzyme Corporation, where he had most recently served as Senior Vice President, Clinical Development and Global Therapeutic Group Head, Oncology and Personalized Genetic Health. While at Genzyme, he played a central role in the development and approval of medicines such as Fabrazyme®, Aldurazyme®, Myozyme®, Lumizyme®, and Mozobil®. Prior to working at Genzyme, he was a full-time staff physician at Brigham and Women's Hospital and Dana Farber Cancer Institute.  He holds appointments at Brigham and Women's Hospital and Dana Farber Cancer Institute and is  also an Associate Professor of Medicine (part time) at Harvard Medical School. Dr. Goldberg received his A.B. (magna cum laude) from Harvard College and his M.D. (cum laude) from Harvard Medical School. He holds Board appointments at Immunogen Corporation, Idera Pharmaceuticals, Glycomimetics, aTyr Pharma, Blueprint Medicines, and the American Cancer Society, New England Division.

 “Dr. Goldberg has served as CANbridge’s advisor since the first days of the company,” said James Xue, CANbridge founder and CEO.  “He has been instrumental in guiding CANbridge through clinical strategy development and due diligence in various business transactions involving U.S. and European companies.  Mark’s global perspective and experiences are invaluable to us as we formulate and implement regional clinical studies that harmonize CANbridge’s effort with those of our Western partners.  I, and the CANbridge team, are honored and excited about Mark taking on this expanded role, which will boost CANbridge’s ability to impact patients’ quality of life in our geographies and beyond.”

  “I am a strong believer of the mission that CANbridge spearheads in Asia,” Dr. Goldberg said. “I am excited to join CANbridge as acting Chief Medical Officer.   James and I worked together extensively when we were both at Genzyme.  CANbridge provides us with the platform to leverage our respective experiences to bring Western life-changing therapies to patients in Asia sooner.”

CANbridge also announced the completion of its Series A plus financing round, with close to $20M raised and committed since incorporation.  Qiming Venture Partners led the round.  TF Capital and Tigermed also participated in the latest round.

“With the additional capital from Series A plus, CANbridge is well-positioned to execute our ongoing development programs and business transactions, particularly as we expand our executive team to include a CMO,” said Mr. Xue. 


About CANbridge Life Sciences

CANbridge Life Sciences, Ltd. is a bio-pharmaceutical company accelerating development and commercialization of specialty healthcare products for serious and critical medical conditions in China and North Asia (Korea and Taiwan).  CANbridge develops partnerships with Western bio-pharmaceutical companies with clinical-stage pharmaceutical, medical device or diagnostic products that are either unavailable in China/North Asia or address medical needs that are underserved in the region. CANbridge also licenses or obtains exclusive rights to commercialize drug and device products that are approved in their home markets for commercialization in China and North Asia.   CANbridge has an exclusive licensing agreement with U.S.-based Azaya Therapeutics, Inc., to develop and commercialize ATI-1123 in China, for the treatment of non-small cell lung cancer and other solid tumors. CANbridge also has an agreement with EUSA Pharma, to commercialize Caphosol® in China for the prevention and treatment of oral mucositis caused by cancer treatments, and a license with Apogenix to develop, manufacture and commercialize lead candidate, onco-immunotherapy, APG101, for the treatment of glioblastoma multiforme in China, Macao and Hong Kong.

Led and backed by a -seasoned executive team with extensive Chinese drug development experience, CANbridge has the capability to select, acquire, develop and commercialize future therapeutics and diagnostics targeting the unmet medical needs of Chinese and East Asian patients with serious or critical conditions.  

CANbridge is privately-held and headquartered in Beijing, China.  For more on CANbridge Life Sciences, please go to




James Xue                                                                    






Deanne Eagle

Planet Communications